362 related articles for article (PubMed ID: 9613749)
1. Apomorphine-induced penile erections in Parkinson's disease.
O'Sullivan JD; Hughes AJ
Mov Disord; 1998 May; 13(3):536-9. PubMed ID: 9613749
[TBL] [Abstract][Full Text] [Related]
2. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
3. [Subcutaneous apomorphine in the treatment of Parkinson's disease].
Linazasoro G
Neurologia; 1994 Jan; 9(1):1-3. PubMed ID: 8161461
[TBL] [Abstract][Full Text] [Related]
4. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
Manson AJ; Turner K; Lees AJ
Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
[TBL] [Abstract][Full Text] [Related]
5. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
[TBL] [Abstract][Full Text] [Related]
6. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
Stacy M; Silver D
Parkinsonism Relat Disord; 2008; 14(2):85-92. PubMed ID: 18083605
[TBL] [Abstract][Full Text] [Related]
7. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease.
Tison F; Wiart L; Guatterie M; Fouillet N; Lozano V; Henry P; Barat M
Mov Disord; 1996 Nov; 11(6):729-32. PubMed ID: 8914103
[TBL] [Abstract][Full Text] [Related]
8. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
[TBL] [Abstract][Full Text] [Related]
9. Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease.
Priano L; Albani G; Calderoni S; Baudo S; Lopiano L; Rizzone M; Astolfi V; Cavalli R; Gasco MR; Fraschini F; Bergamasco B; Mauro A
Neurol Sci; 2002 Sep; 23 Suppl 2():S99-100. PubMed ID: 12548362
[TBL] [Abstract][Full Text] [Related]
10. Stimulation of dopamine receptors in the paraventricular nucleus of the hypothalamus of male rats induces penile erection and increases extra-cellular dopamine in the nucleus accumbens: Involvement of central oxytocin.
Succu S; Sanna F; Melis T; Boi A; Argiolas A; Melis MR
Neuropharmacology; 2007 Mar; 52(3):1034-43. PubMed ID: 17164075
[TBL] [Abstract][Full Text] [Related]
11. Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response.
Maggio R; Barbier P; Corsini GU
J Neural Transm Suppl; 1995; 45():133-6. PubMed ID: 8748618
[TBL] [Abstract][Full Text] [Related]
12. Differential response in choice reaction time following apomorphine based on prior dopaminergic treatment.
Müller T; Benz S; Börnke C; Przuntek H
Acta Neurol Scand; 2004 May; 109(5):348-54. PubMed ID: 15080862
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories.
van Laar T; Jansen EN; Neef C; Danhof M; Roos RA
Mov Disord; 1995 Jul; 10(4):433-9. PubMed ID: 7565822
[TBL] [Abstract][Full Text] [Related]
14. [Subcutaneous apomorphine infusion in the treatment of Parkinson disease].
Albani C; Zangger I; Fischer G
Schweiz Rundsch Med Prax; 1992 Aug; 81(35):1011-5. PubMed ID: 1410978
[TBL] [Abstract][Full Text] [Related]
15. Addiction to apomorphine: a clinical case-centred discussion.
Téllez C; Bustamante ML; Toro P; Venegas P
Addiction; 2006 Nov; 101(11):1662-5. PubMed ID: 17034447
[TBL] [Abstract][Full Text] [Related]
16. PD-168077, a selective dopamine D4 receptor agonist, induces penile erection when injected into the paraventricular nucleus of male rats.
Melis MR; Succu S; Mascia MS; Argiolas A
Neurosci Lett; 2005 Apr; 379(1):59-62. PubMed ID: 15814200
[TBL] [Abstract][Full Text] [Related]
17. Sublingual apomorphine: a new pharmacological approach in Parkinson's disease?
Montastruc JL; Rascol O; Senard JM; Houin G; Rascol A
J Neural Transm Suppl; 1995; 45():157-61. PubMed ID: 8748621
[TBL] [Abstract][Full Text] [Related]
18. [Shifting to subcutaneous infusion of apomorphine in advanced Parkinson's disease patients on an out-patient basis: experience and recommendations].
Castaño B; Mateo D; Giménez-Roldán S
Neurologia; 2007 Apr; 22(3):133-7. PubMed ID: 17364250
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study.
García Ruiz PJ; Sesar Ignacio A; Ares Pensado B; Castro García A; Alonso Frech F; Alvarez López M; Arbelo González J; Baiges Octavio J; Burguera Hernández JA; Calopa Garriga M; Campos Blanco D; Castaño García B; Carballo Cordero M; Chacón Peña J; Espino Ibáñez A; Gorospe Onisalde A; Giménez-Roldán S; Granés Ibáñez P; Hernández Vara J; Ibáñez Alonso R; Jiménez Jiménez FJ; Krupinski J; Kulisevsky Bojarsky J; Legarda Ramírez I; Lezcano García E; Martínez-Castrillo JC; Mateo González D; Miquel Rodríguez F; Mir P; Muñoz Fargas E; Obeso Inchausti J; Olivares Romero J; Olivé Plana J; Otermin Vallejo P; Pascual Sedano B; Pérez de Colosía Rama V; Pérez López-Fraile I; Planas Comes A; Puente Periz V; Rodríguez Oroz MC; Sevillano García D; Solís Pérez P; Suárez Muñoz J; Vaamonde Gamo J; Valero Merino C; Valldeoriola Serra F; Velázquez Pérez JM; Yáñez Baña R; Zamarbide Capdepon I
Mov Disord; 2008 Jun; 23(8):1130-6. PubMed ID: 18442107
[TBL] [Abstract][Full Text] [Related]
20. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease.
Wenning GK; Bösch S; Luginger E; Wagner M; Poewe W
Adv Neurol; 1999; 80():545-8. PubMed ID: 10410769
[No Abstract] [Full Text] [Related]
[Next] [New Search]